BLASINGLE-USEVIAL
Approved
Jun 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Mechanism of Action
erythropoietin.
Indications (12)
anemia due to chronic kidney disease (CKD)including patients on dialysisnot on dialysis to decrease the need for red blood cell (RBC) transfusionanemia due to zidovudine administered at ≤ 4200 mg/week in patients with HIV Infection with endogenous serum erythropoietin levels of ≤ 500 mUnits/mLanemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapyupon initiationthere is a minimum of two additional months of planned chemotherapyneed for allogeneic RBC transfusions among patients with perioperative hemoglobin > 10 to ≤ 13 g/dLnoncardiacnonvascular surgeryanemiaChronic Kidney Disease
Clinical Trials (5)
Incidence and Clinical Burden of Erythropoietin Hyporesponsiveness - a Retrospective Database Analysis
Started Nov 2022
85,259 enrolled
Chronic Kidney Disease
Impact of Erythropoietin on Hematological Adaptations and Physical Performance
Started Sep 2021
8 enrolled
Exercise-Induced AnemiaPhysical Performance
A Study to Investigate the Effect of Roxadustat Versus Recombinant Human Erythropoietin (rHuEPO) on Oral Iron Absorption in Chinese Patients With Anemia of Chronic Kidney Disease (CKD)
Started Feb 2021
25 enrolled
Anemia of Chronic Kidney Disease
High-dose Erythropoietin for Asphyxia and Encephalopathy
Started Jan 2017
Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients
Started Nov 2015